• Search
  • Contacts
  • eMS
  • About EstLat
    • Interreg Estonia-Latvia
    • Interreg30
    • Programme status
    • Programme 2021-2027
    • Programme area
    • Financial overview
    • Programme management
    • Evaluation and surveys
    • Annual reports
  • We support
    • Entrepreneurship
    • Heritage tourism
    • Environmental awareness
    • Water management
    • Valga-Valka central urban area
    • Harmonized geodetic systems
    • Small harbours
    • Labour commuters
  • Supported projects
  • For projects
    • Guiding documents
    • Agreements
    • Reporting
    • Project changes
    • European Cooperation Day
    • Logos and disclaimer
    • Poster templates and SO pictures
    • Useful information
  • For applicants
    • Results of calls
    • For pre-defined projects
    • eMS
    • Consultations
    • Organizations for partner search
  • EstLat Results
    • walk VVALK 2020
    • 30 trees for Interreg 30
    • LAMPA conversation and LAMPA Interreg Hike
    • Interreg30 Anniversary Hike
    • Moments with ESTLAT
    • Green Space Tour 2019
    • Heritage Road Trip 2018
    • Ape - Vastse-Roosa 2017
    • Lilli – Ķoņi 2016
    • Treimani – Ainaži 2015
    • Stopover Celebration 2014
    • Estonia-Latvia Stories
    • Cartoons summarizing 2007-2013
    • EE-LV Road Trip 2013
    • Better neighbors 2012
    • Supported projects 2007-2013
  • Events
{{ menu_link }}
  • Home
  • EstLat Results
  • PET-Diagnostics
EstLat Results

PET-Diagnostics

Overview
Project lead partner: TBD-Biodiscovery Ltd
Partners: PharmIdea Ltd
Topic: SME cooperation
Start date: 2017-03-01
End date: 2019-05-31
View partners on map

Development of Positron Emission Tomography (PET) precursor

Total budget:
€ 580 886.74
ERDF contribution:
€ 480 754.52
Contact person:
Triin Käbin
kkevvai@biodiscovery.eu
Status:
Completed

Positron emission tomography/computed tomography (PET/CT-scanning) is becoming the most versatile diagnostic tool for early/metastatic cancer detection as well as an examination of Parkinson and Alzheimer's patients. The project partners TBD-Biodiscovery (Estonia) and PharmIdea (Latvia) have the competences and experience necessary to enter the PET diagnostic market: production of active ingredients and final dosage drug forms.

 

The aim of the project was to develop technology for the production of the PET precursor for diagnostics. This molecule can be used for the early diagnosis of prostate cancer, one of the most common cancers in men in Europe and worldwide. In addition to early diagnosis, PET prcursor could be used in patient health control for remission (after chemotherapy or radiation therapy) and for the diagnosis of small metastatic tumors in advanced cancer. TBD-Biodiscovery was responsible for the development of the production method and GMP validation, and PharmIdea continued to develop quality control methods and stability studies. 

The outcome of the project is the final dosage form of the PET-product with the package of supporting documentation, necessary for its implementation in nuclear medicine centers and hospitals.


Achievements of the project:

  1. Collection of the market, patent, and scientific data in close cooperation of partners,
  2. Final selection of PET-product, which has full freedom to operate in the European Union and worldwide and preparation of several intermediates and building blocks for the synthesis of PET precursor,
  3. Synthesized first samples of the PET-product, used for early diagnostics of prostate cancer, and fully identified structure using modern analytical methods, 
  4. Successful process validation and development of an analytical method for both the PET-product and its drug form,
  5. Successful technological process development and validation for the production of PET products which can be implemented for routine production in the future,
  6. Successful compilation of CTD Module 3 documentation,
  7. Starting and continuing the stability studies, both short term, and long term,
  8. Organization of the biotech/pharma matchmaking event in Riga (Latvia).

 

 

To reach the general public, TBD-Biodiscovery contacted multiple hospitals, science centers, and research facilities and different unions (e.g. cancer societies, doctor societies), in total 200 different facilities were contacted. Also, both partners have actively looked for innovative companies already active in the area of nuclear medicine or developing new products/methods for PET-diagnostics and big pharma companies looking for new products with high added value.

Share this story

  • Share on Facebook
  • Share on Twitter
  • Share on Draugiem
What's Estlat?
Title 1
Title 2
Title 3
Title 4
Title 5
Title 6
We Support
Title 1
Title 2
Title 3
For Applicants
Title 1
Title 2
Title 3
Title 4
Title 5
For Projects
Title 1
Title 2
Title 3
Title 4
Title 5
Title 6
Estlat Results
Title 1
Title 2
Title 3
Title 4
Title 5
Title 6
What's Estlat?
Login Contact eMS

Programme JS Office in Tartu:

Sõbra 56, 50106 Tartu, Estonia

Information and Consultation Point in Rīga:

Alberta iela 10 – 410. (4th floor), Riga, LV-1010, Latvia

  • Sitemap
Subscribe for news:
Subscribed!
  • Facebook
  • Youtube
Forgot password?